Diffusion Pharmaceuticals Inc. [NASDAQ: DFFN] slipped around -0.1 points on Friday, while shares priced at $1.24 at the close of the session, down -7.46%. The company report on February 12, 2021 that Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million.
Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.
H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.
Diffusion Pharmaceuticals Inc. stock is now 55.97% up from its year-to-date (YTD) trading value. DFFN Stock saw the intraday high of $1.35 and lowest of $1.09 per share. The company’s 52-week high price is 1.60, which means current price is +54.40% above from all time high which was touched on 02/10/21.
Compared to the average trading volume of 3.85M shares, DFFN reached a trading volume of 74609320 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Diffusion Pharmaceuticals Inc. [DFFN]?
H.C. Wainwright have made an estimate for Diffusion Pharmaceuticals Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on November 17, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on March 21, 2018, representing the official price target for Diffusion Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Diffusion Pharmaceuticals Inc. is set at 0.18 The Price to Book ratio for the last quarter was 2.76, with the Price to Cash per share for the same quarter was set at 0.32.
How has DFFN stock performed recently?
Diffusion Pharmaceuticals Inc. [DFFN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.88. With this latest performance, DFFN shares dropped by -0.80% in over the last four-week period, additionally plugging by 19.23% over the last 6 months – not to mention a rise of 193.84% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DFFN stock in for the last two-week period is set at 53.42, with the RSI for the last a single of trading hit 49.37, and the three-weeks RSI is set at 55.17 for Diffusion Pharmaceuticals Inc. [DFFN]. The present Moving Average for the last 50 days of trading for this stock 0.9933, while it was recorded at 1.3920 for the last single week of trading, and 0.9552 for the last 200 days.
Diffusion Pharmaceuticals Inc. [DFFN]: Deeper insight into the fundamentals
Diffusion Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.40 and a Current Ratio set at 8.40.
Earnings analysis for Diffusion Pharmaceuticals Inc. [DFFN]
With the latest financial reports released by the company, Diffusion Pharmaceuticals Inc. posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 15.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DFFN.
Insider trade positions for Diffusion Pharmaceuticals Inc. [DFFN]
There are presently around $6 million, or 10.40% of DFFN stock, in the hands of institutional investors. The top three institutional holders of DFFN stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 2,832,739, which is approximately -5.214% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 830,471 shares of the stock with an approximate value of $1.03 million in DFFN stocks shares; and VANGUARD GROUP INC, currently with $0.49 million in DFFN stock with ownership of nearly 11.624% of the company’s market capitalization.
8 institutional holders increased their position in Diffusion Pharmaceuticals Inc. [NASDAQ:DFFN] by around 251,053 shares. Additionally, 13 investors decreased positions by around 642,386 shares, while 7 investors held positions by with 3,935,736 shares. The mentioned changes placed institutional holdings at 4,829,175 shares, according to the latest SEC report filing. DFFN stock had 5 new institutional investments in for a total of 110,398 shares, while 8 institutional investors sold positions of 407,947 shares during the same period.